| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
β-Adrenergic receptor; Methyl maslinate acts as an antagonist of the β-adrenergic receptor. By blocking this receptor, it exerts cardiotonic and antidysrhythmic effects. The β-adrenergic receptor is a GPCR that plays a key role in the regulation of heart rate and contractility. Antagonism of this receptor leads to decreased heart rate (sinus bradycardia) and reduced blood pressure (vasodepressor effect). This mechanism underlies its potential use in hypertension research.
|
|---|---|
| ln Vitro |
In vitro studies on Methyl maslinate are limited. The compound is primarily characterized by its in vivo cardiovascular effects. It is known to antagonize β-adrenergic receptors. The compound shows cardiotonic activity, suggesting positive inotropic effects on the heart, although the exact in vitro mechanisms are not extensively documented. It may be used in cell-based assays to study β-adrenergic receptor signaling and cardiovascular function.
|
| ln Vivo |
Methylmaslinate (MM) (20–60 mg/kg; intraperitoneally) demonstrates a noteworthy, dose-dependent vasodepression and sinus bradycardia that lasts for more than 60 minutes, peaking at 20 minutes [1]. It also has an efficient hydrodynamic action. For ischemia-reperfusion arrhythmias, methyl maslinate (40 mg/kg) exhibits antiarrhythmic action [1].
In vivo, Methyl maslinate (20-60 mg/kg; i.p.) shows significant, dose-response vasodepressor effect and sinus bradycardia in Wistar male rats. The effects last more than 60 minutes with a maximum at 20 minutes. At 40 mg/kg, it shows antidysrhythmic activity on ischemia-reperfusion dysrhythmia. These results indicate potent hemodynamic effects and support its potential for hypertension research. The compound is administered via intraperitoneal injection. |
| Enzyme Assay |
Specific in vitro assay protocols for Methyl maslinate are not extensively documented in the available literature. The compound is known to antagonize β-adrenergic receptors. In cell-based assays, it could be used to study β-adrenergic receptor signaling, cAMP production, and downstream effects on cell function. However, detailed protocols, such as cell lines, concentrations, and incubation times, are not publicly available. Researchers would need to establish appropriate protocols based on the specific research objectives and published literature on β-adrenergic receptor antagonists.
|
| Animal Protocol |
Animal/Disease Models: Wistar male rat (300-320 g) [1]
Doses: 20-60 mg/kg Route of Administration: intraperitoneal (ip) injection; primary Experimental Results: demonstrated significant, dose-responsive vasopressor effect and sinus tachycardia slow. Antagonizes beta-adrenergic activity. Displays antiarrhythmic activity. In vivo animal models are used to study the cardiovascular effects of Methyl maslinate. Wistar male rats (300-320 g) are administered the compound via intraperitoneal injection at doses of 20-60 mg/kg. The animals are monitored for vasodepressor effect, sinus bradycardia, and antidysrhythmic activity. The effects are measured over time, with the maximum effect observed at 20 minutes and lasting more than 60 minutes. This protocol is used to evaluate the compound's potential for hypertension and cardiovascular disease research. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Methyl maslinate are not extensively documented. The compound is administered intraperitoneally in animal studies. It has a molecular weight of 486.73, indicating it is a relatively large lipophilic molecule. It is expected to be absorbed and distributed to tissues, but specific parameters such as half-life, volume of distribution, and clearance are not available. The compound is for research use only and not for human therapeutic use. Further studies are needed to fully characterize its ADME properties.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Methyl maslinate are not extensively documented. As a β-adrenergic receptor antagonist, it may cause cardiovascular effects such as bradycardia and hypotension at high doses. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions, including the use of personal protective equipment. The compound should be stored in a sealed container in a cool, dry place. Further toxicological studies are needed to determine its safety profile.
|
| References | |
| Additional Infomation |
According to reports, methyl masrin is found in Japanese chamomile, loosestrife, and other organisms with available data.
Methyl maslinate is also known as maslinic acid methyl ester. It is a β-adrenergic receptor antagonist with cardiotonic and antidysrhythmic properties. It has potential for hypertension research. In vivo, it shows significant, dose-dependent vasodepressor effects and sinus bradycardia. It also shows antidysrhythmic activity on ischemia-reperfusion dysrhythmia. The compound is supplied as a solid and should be stored at low temperature. It is for research use only. |
| Molecular Formula |
C31H50O4
|
|---|---|
| Molecular Weight |
486.7263
|
| Exact Mass |
486.371
|
| CAS # |
22425-82-7
|
| PubChem CID |
13653327
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.11g/cm3
|
| Boiling Point |
541.9ºC at 760mmHg
|
| Flash Point |
163.1ºC
|
| Vapour Pressure |
5.29E-14mmHg at 25°C
|
| Index of Refraction |
1.552
|
| LogP |
6.292
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
35
|
| Complexity |
934
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
COC([C@@]12CC[C@]3([C@@]4(CCC5C([C@H]([C@@H](C[C@]5(C)[C@H]4CC=C3[C@H]1CC(CC2)(C)C)O)O)(C)C)C)C)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0545 mL | 10.2726 mL | 20.5453 mL | |
| 5 mM | 0.4109 mL | 2.0545 mL | 4.1091 mL | |
| 10 mM | 0.2055 mL | 1.0273 mL | 2.0545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
